RARE DISEASERESEARCH ATLAS

ORPHA:231500

Hermansky-Pudlak syndrome due to BLOC-3 deficiency

high confidenceSubtype of disorder

Also known as: HPS with pulmonary fibrosis · Hermansky-Pudlak syndrome with pulmonary fibrosis

Publications

90

50.7th percentile

Trials

0

Interventional, condition-specific

Researchers

556

Distinct authors in sample

Gene link

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A form of Hermansky-Pudlak syndrome characterized by oculocutaneous albinism, bleeding diathesis and pulmonary fibrosis or granulomatous colitis, but without neutropenia. Hermansky-Pudlak syndrome due to BLOC-3 deficiency has a severe prognosis and includes two genetic etiologies (HPS1 and HPS4).

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    90 matched papers (62 in last 10 years) Source

  3. Phenotype characterisedPresent

    36 HPO annotations (e.g. Horizontal nystagmus; Hypopigmentation of hair; Renal insufficiency) Source

  4. Animal modelPresent

    8 genotype models (Mus musculus) Source

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPartial

    None under the specific name; 4 for broader category Hermansky-Pudlak syndrome

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

36

Associated phenotypes · MONDO:0016501

  • Horizontal nystagmus
  • Hypopigmentation of hair
  • Renal insufficiency
  • Colitis
  • Bruising susceptibility

Showing 5 of 36 — open Monarch for the full list.

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

90

90 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

90 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

62 in the last 10 years · high confidence · 50.7th percentile (publications denominator)

Phrase hits: 90 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

556

Distinct author names in 90 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Gochuico BR20 papers · 2025

    Medical Genetics Branch, National Human Genome Research Institute (NHGRI), NIH, Bethesda, Maryland, USA.

    Papers in Europe PMC
  2. 02
    Gahl WA17 papers · 2022

    Medical Genetics Branch, National Human Genome Research Institute (NHGRI), NIH, Bethesda, Maryland, USA.

    Papers in Europe PMC
  3. 03
    Huizing M8 papers · 2020

    Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

    Papers in Europe PMC
  4. 04
    O'Brien KJ8 papers · 2025

    Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States.

    Papers in Europe PMC
  5. 05
    Young LR8 papers · 2025

    Division of Pulmonary Medicine, Department of Pediatrics, Vanderbilt University School of Medicine, 2200 Children's Way, 11215 Doctor's Office Tower, Nashville, TN 37232, USA. Lisa.Young@vanderbilt.edu

    Papers in Europe PMC
  6. 06
    Malicdan MCV6 papers · 2023

    Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, United States.

    Papers in Europe PMC
  7. 07
    Zhou Y6 papers · 2026

    Department of Molecular Microbiology and Immunology, Division of Medicine and Biologic Sciences, Brown University, Providence, Rhode Island, USA.

    Papers in Europe PMC
  8. 08
    El-Chemaly S5 papers · 2022

    Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, United States.

    Papers in Europe PMC
  9. 09
    Merideth MA5 papers · 2025

    Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892-1851, USA. mmeridet@mail.nih.gov

    Papers in Europe PMC
  10. 10
    Rosas IO5 papers · 2022

    Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 4 trials are registered for Hermansky-Pudlak syndrome, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

4 interventional trials matched Hermansky-Pudlak syndrome, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: Hermansky-Pudlak syndrome

4

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (1)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Hermansky-Pudlak syndrome due to BLOC-3 deficiency — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Hermansky-Pudlak syndrome due to BLOC-3 deficiency" OR "HPS with pulmonary fibrosis" OR "Hermansky-Pudlak syndrome with pulmonary fibrosis"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Hermansky-Pudlak syndrome due to BLOC-3 deficiency" OR "HPS with pulmonary fibrosis" OR "Hermansky-Pudlak syndrome with pulmonary fibrosis"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"Hermansky-Pudlak syndrome"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T10:17:55.434Z